Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors. Furthermore, using them together with a powerful bioprocess controller like the BioFlo® 320 enables precise cell culture parameter control and seamless process transition to up to 40 L of working volume.
BioBLU® Single-Use Bioreactors and BioFlo® 320 bioprocess controller – Single-Use Simplicity Under Control
ProductsSingle-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors. Furthermore, using them together with a powerful bioprocess controller like the BioFlo® 320 enables precise cell culture parameter control and seamless process transition to up to 40 L of working volume.
Consortium led by Evotec enters obesity drug space
Latest NewsDrug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases.
Semarion Ltd. wins Ignite SME award at SLAS Europe
Associations, Latest NewsUK-based Semarion Ltd. was honoured as the most innovative company in the field of laboratory automation at SLAS Europe 2024 in Barcelona.
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
Latest NewsUS pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones.
Where has the conviction gone?
Opinion2023 was another particularly tumultuous year for life sciences and, although the lingering effects of the last year are unlikely to change dramatically, the stabilisation of interest rates (off 16-year highs) and emerging direction of travel (market data points) tilt our bias to positive for the new year.
Interims CEO takes over
AppointmentsIn November 2023, Enhanc3D Genomics appointed Dr Hazel Jones as interim CEO and COO. Now she has taken over the Position of CEO officially.
SLAS Europe 2024 honours products with most impact
Latest NewsSwiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector.
Cancer research on three pillars
Sponsored PublicationsOver the past few years, the Frankfurt Institute of Clinical Cancer Research (IKF) has successfully conducted over 90 clinical studies. Each year, it enrolls approximately 1,500 patients in these trials. European Biotechnology spoke with the founder and director Prof. Dr med. Salah-Eddin Al-Batran.
Hornet Therapeutics reports first data of EBV-triggered disease blocker
Latest NewsHornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.
The future of health biotech innovation in Europe
OpinionThe 2023 State of the Union speech saw biotechnology rise as a priority for the European Union. It has been designated as a critical technology for Europe’s economic security. In March 2024, the European Commission presented its biotechnology and biomanufacturing strategy with a clear leadership ambition for Europe’s biotech industries. The Letta Report on the future of the Single Market, published April 2024, proposed a fifth freedom on research and innovation which would directly benefit biotech.